Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.

Soeung M, Yan X, Zanca C, Qian J, Karki M, Duan F, Khan H, Zhang L, Peng DH, Williams M, He R, Chen Z, Perelli L, Chen J, Tidwell RS, Chauhan PK, Le CN, Lam TNA, Bhattacharya N, Shah R, Ho IL, Gay JP, Carrillo CC, Feng N, Le K, Gao G, Perry TL, Mseeh F, Jiang Y, Xu QA, Zacharias NM, Sheth RA, Bathala TK, Rao P, Daw NC, Tripathi DN, Walker CL, Mohammad MM, Zhang J, Han G, Chu Y, Wang R, Dang M, Dai E, Peng F, Liu Y, Jadhav A, Lang W, Arrechedera CA, Clemente LC, Parra ER, Lu H, Haymaker CL, Wistuba II, Futreal A, Viale A, Soth MJ, Jones P, Marszalek JR, Heffernan T, Draetta GF, Tannir NM, Gao J, Wang L, Genovese G, Msaouel P

Open source

DOI: 10.1038/s41467-025-65462-z
Published: 2025 Nov 25
Container: Nature communications
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-025-65462-z,
  title = {Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.},
  author = {Soeung M and Yan X and Zanca C and Qian J and Karki M and Duan F and Khan H and Zhang L and Peng DH and Williams M and He R and Chen Z and Perelli L and Chen J and Tidwell RS and Chauhan PK and Le CN and Lam TNA and Bhattacharya N and Shah R and Ho IL and Gay JP and Carrillo CC and Feng N and Le K and Gao G and Perry TL and Mseeh F and Jiang Y and Xu QA and Zacharias NM and Sheth RA and Bathala TK and Rao P and Daw NC and Tripathi DN and Walker CL and Mohammad MM and Zhang J and Han G and Chu Y and Wang R and Dang M and Dai E and Peng F and Liu Y and Jadhav A and Lang W and Arrechedera CA and Clemente LC and Parra ER and Lu H and Haymaker CL and Wistuba II and Futreal A and Viale A and Soth MJ and Jones P and Marszalek JR and Heffernan T and Draetta GF and Tannir NM and Gao J and Wang L and Genovese G and Msaouel P},
  year = {2025},
  journal = {Nature communications},
  doi = {10.1038/s41467-025-65462-z},
  url = {https://doi.org/10.1038/s41467-025-65462-z}
}

RIS

TY  - JOUR
TI  - Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.
AU  - Soeung M
AU  - Yan X
AU  - Zanca C
AU  - Qian J
AU  - Karki M
AU  - Duan F
AU  - Khan H
AU  - Zhang L
AU  - Peng DH
AU  - Williams M
AU  - He R
AU  - Chen Z
AU  - Perelli L
AU  - Chen J
AU  - Tidwell RS
AU  - Chauhan PK
AU  - Le CN
AU  - Lam TNA
AU  - Bhattacharya N
AU  - Shah R
AU  - Ho IL
AU  - Gay JP
AU  - Carrillo CC
AU  - Feng N
AU  - Le K
AU  - Gao G
AU  - Perry TL
AU  - Mseeh F
AU  - Jiang Y
AU  - Xu QA
AU  - Zacharias NM
AU  - Sheth RA
AU  - Bathala TK
AU  - Rao P
AU  - Daw NC
AU  - Tripathi DN
AU  - Walker CL
AU  - Mohammad MM
AU  - Zhang J
AU  - Han G
AU  - Chu Y
AU  - Wang R
AU  - Dang M
AU  - Dai E
AU  - Peng F
AU  - Liu Y
AU  - Jadhav A
AU  - Lang W
AU  - Arrechedera CA
AU  - Clemente LC
AU  - Parra ER
AU  - Lu H
AU  - Haymaker CL
AU  - Wistuba II
AU  - Futreal A
AU  - Viale A
AU  - Soth MJ
AU  - Jones P
AU  - Marszalek JR
AU  - Heffernan T
AU  - Draetta GF
AU  - Tannir NM
AU  - Gao J
AU  - Wang L
AU  - Genovese G
AU  - Msaouel P
PY  - 2025
JO  - Nature communications
DO  - 10.1038/s41467-025-65462-z
UR  - https://doi.org/10.1038/s41467-025-65462-z
ER  -

APA

M, S., X, Y., C, Z., J, Q., M, K., F, D., H, K., L, Z., DH, P., M, W., R, H., Z, C., L, P., J, C., RS, T., PK, C., CN, L., TNA, L., N, B., R, S., IL, H., JP, G., CC, C., N, F., K, L., G, G., TL, P., F, M., Y, J., QA, X., NM, Z., RA, S., TK, B., P, R., NC, D., DN, T., CL, W., MM, M., J, Z., G, H., Y, C., R, W., M, D., E, D., F, P., Y, L., A, J., W, L., CA, A., LC, C., ER, P., H, L., CL, H., II, W., A, F., A, V., MJ, S., P, J., JR, M., T, H., GF, D., NM, T., J, G., L, W., G, G., & P, M. (2025). Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.. Nature communications. https://doi.org/10.1038/s41467-025-65462-z

Source records

pubmed · retrieved 2026-09-26T20:26:12.042Z